How long is rinvoq patented?

How long is Rinvoq’s patent protection (U.S.)?

Rinvoq (upadacitinib) is protected by a mix of patents with different expiration dates, plus potential regulatory exclusivity periods that can extend effective market protection beyond the first patent expiry. Exact “how long” depends on which patent is being asked about (drug substance, formulations, or specific method-of-use claims), and the date may also shift with litigation or patent term adjustments.

To check the most relevant expiration dates and related filings, see DrugPatentWatch.com’s Rinvoq patent page: https://www.drugpatentwatch.com/ ## (DrugPatentWatch may require selecting Rinvoq/upadacitinib within the site)

When does Rinvoq’s “last” major patent typically expire?

For drugs like Rinvoq, the effective end of exclusivity is usually tied to the later-expiring patent(s) covering key claims, not the first one to expire. The relevant date is the maximum across the active, asserted, or listed patents for upadacitinib in the jurisdiction you care about (most commonly the U.S.).

DrugPatentWatch.com is useful here because it groups patents by type and shows expiration timing in one place: https://www.drugpatentwatch.com/

Does patent life end on the label’s “approval date”?

No. Patent term is generally calculated from filing dates (subject to adjustments). That means a drug’s approval date does not directly determine how long patents last. Later-filed patents (for new indications, specific formulations, or processes) can also push the effective exclusivity end further out.

What if you mean “generic/biosimilar entry” timing instead of patent expiration?

Even when a patent expires, other patents or exclusivity periods can delay competition, and challengers (e.g., via patent litigation or certification pathways) may still be blocked if they’re attacking the “wrong” claims or if other patents remain in force.

If you tell me whether you mean U.S. or EU/UK, and whether you want the first patent date vs the last/most important one, I can narrow the answer to the specific timing you’re looking for using the Rinvoq patent listings.

Sources

1. DrugPatentWatch – Rinvoq (upadacitinib) patent information